133 related articles for article (PubMed ID: 21820182)
21. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC
Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888
[TBL] [Abstract][Full Text] [Related]
22. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
23. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
Nelson JC
Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
[TBL] [Abstract][Full Text] [Related]
24. Electroretinographic anomalies in medicated and drug free patients with major depression: Tagging the developmental roots of major psychiatric disorders.
Hébert M; Mérette C; Paccalet T; Gagné AM; Maziade M
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():10-15. PubMed ID: 28007463
[TBL] [Abstract][Full Text] [Related]
25. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
26. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.
Mancini M; Perna G; Rossi A; Petralia A
Expert Opin Pharmacother; 2010 May; 11(7):1167-81. PubMed ID: 20402555
[TBL] [Abstract][Full Text] [Related]
27. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
28. NGF serum levels variations in major depressed patients receiving duloxetine.
Martino M; Rocchi G; Escelsior A; Contini P; Colicchio S; de Berardis D; Amore M; Fornaro P; Fornaro M
Psychoneuroendocrinology; 2013 Sep; 38(9):1824-8. PubMed ID: 23507186
[TBL] [Abstract][Full Text] [Related]
29. Duloxetine: a review of its use in the treatment of major depressive disorder.
Frampton JE; Plosker GL
CNS Drugs; 2007; 21(7):581-609. PubMed ID: 17579500
[TBL] [Abstract][Full Text] [Related]
30. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
31. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
Sheehan DV; Harnett-Sheehan K; Spann ME; Thompson HF; Prakash A
Int Clin Psychopharmacol; 2011 Mar; 26(2):75-83. PubMed ID: 21102344
[TBL] [Abstract][Full Text] [Related]
32. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression.
Rosso G; Rigardetto S; Bogetto F; Maina G
J Affect Disord; 2012 Jan; 136(1-2):172-176. PubMed ID: 21862138
[TBL] [Abstract][Full Text] [Related]
33. A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy.
Lai CH; Hsu YY
Int J Neuropsychopharmacol; 2011 Mar; 14(2):225-35. PubMed ID: 20663271
[TBL] [Abstract][Full Text] [Related]
34. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
35. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
Oakes TM; Myers AL; Marangell LB; Ahl J; Prakash A; Thase ME; Kornstein SG
Hum Psychopharmacol; 2012 Jan; 27(1):47-56. PubMed ID: 22241678
[TBL] [Abstract][Full Text] [Related]
36. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity.
Wise TN; Wiltse CG; Iosifescu DV; Sheridan M; Xu JY; Raskin J
Int J Clin Pract; 2007 Aug; 61(8):1283-93. PubMed ID: 17590215
[TBL] [Abstract][Full Text] [Related]
37. Time course of depression-symptom improvement during treatment with duloxetine.
Hirschfeld RM; Mallinckrodt C; Lee TC; Detke MJ
Depress Anxiety; 2005; 21(4):170-7. PubMed ID: 16035056
[TBL] [Abstract][Full Text] [Related]
38. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.
Acharya N; Rosen AS; Polzer JP; D'Souza DN; Perahia DG; Cavazzoni PA; Baldessarini RJ
J Clin Psychopharmacol; 2006 Dec; 26(6):587-94. PubMed ID: 17110815
[TBL] [Abstract][Full Text] [Related]
39. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
40. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
Pritchett YL; Marciniak MD; Corey-Lisle PK; Berzon RA; Desaiah D; Detke MJ
J Psychiatr Res; 2007; 41(3-4):311-8. PubMed ID: 16934840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
